Wonka. For whatever reason the product to Symtomax was delayed. Be it Corona or whatever. If the product was delivered after March 31, 2020 it won't show up as revenue until Q2. I doubt Symtomax would pay for product if not received and usually there are terms as well. Net 30 etc. Also I think you meant the part where GCAN showed no sales (revenue) not Symtomax. GCAN has put out a product, through Symtomax, from concept to reality in 17 months. Pretty quick timeline if you ask me. The real issue is silence from the company. Everyone can agree with that I'm sure.
NO, WHAT I MEANT WAS THAT WHEN I SAW THE Q, I WAS FRANKLY DISGUSTED AT THE PART WHERE IT STATED SYMTOMAX MADE NO SALES AS OF YET. LAST NIGHT HOWEVER, I NOTICED A REVIEW FOR THE 30 PACK ORALTABS AND THAT THE SITE SHOWED PAYMENT CARD OPTIONS. BEFORE I NOTICED THE CHANGES AND REVIEW ON ORALTABS, I STARTED TO TAKE A DIFFERENT PHILOSOPHY TOWARDS GCAN, AS THE Q. SUCKED. BUT AFTER SEEING THE ORALTABS SITE MY OPINION SWITCHED BACK TO LOOK AT GCAN AS A LONGER TERM PLAY AGAIN. I HAVE UNFORTUNATELY NOT SOLD A SHARE FOR OVER A YEAR.